Regeneron Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Director or officer changeSep 30 →InsidersNo open-market buys. 5 insiders sold $9.5M, 71 of 78 sales on a 10b5-1 plan.→HoldersBlackRock $5.68BVanguard $4.13BDodge & Cox $3.04B→PeersClosest companies: VRDN, OCGN, ORIC→
From the filings
Figures
- Revenue
- $15.53Blast 12 months
- Net income
- $4.33Blast 12 months
- Operating cash flow
- $5.01Blast 12 months
- Cash and equivalents
- $2.46Bat the last balance sheet
- Total debt
- $1.99Bat the last balance sheet